NCT03190057 (IRISBioFreedom) is a clinical trial of BIOFREEDOM™ FAMILY stent in Coronary Stenosis, sponsored by Seung-Jung Park.

Who is sponsoring NCT03190057?

NCT03190057 is sponsored by Seung-Jung Park.

What drugs are being tested in NCT03190057?

Interventions in NCT03190057: BIOFREEDOM™ FAMILY stent.

What condition does NCT03190057 study?

NCT03190057 studies Coronary Stenosis.

Is NCT03190057 still recruiting?

NCT03190057 is currently terminated. Last updated 30 September 2025.

Last reviewed 2025-09-30 · How we verify

NCT03190057: IRISBioFreedom

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IRIS-BioFreedom Cohort in the IRIS-DES Registry

Terminated Last updated 30 September 2025

What this trial tests

trial testing BIOFREEDOM™ FAMILY stent in Coronary Stenosis in 218 participants. Terminated before completion.

Timeline

20 May 2019

Primary endpoint
29 September 2025

29 September 2025

Quick facts

Lead sponsor	Seung-Jung Park
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	218
Start date	20 May 2019
Primary completion	29 September 2025
Estimated completion	29 September 2025
Sites	8 locations across South Korea

Drugs / interventions tested

BIOFREEDOM™ FAMILY stent

Conditions studied

Coronary Stenosis — all drugs for Coronary Stenosis →

Sponsor

Seung-Jung Park — full company profile →

Who can join

19 and older, any sex, with Coronary Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate effectiveness and safety of BIOFREEDOM™ FAMILY stent in the "real world" daily practice as compared with other drug-eluting stents.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Stenosis

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
NCT05709652 — Impact of Fast-rotation Coronary CT in Patients Undergoing Aortic Stenosis Workup · NA · recruiting
NCT06376630 — Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI · NA · recruiting
NCT04014140 — iFR Guided Coronary Artery Bypass Grafting Surgery · recruiting

Other Seung-Jung Park trials

Trials by the same sponsor.

NCT06908499 — The DECISION-CTO Extended 10 Y Follow-up · not yet recruiting
NCT06177743 — IRIS-Coroflex NEO Cohort · recruiting
NCT05125367 — Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation i · completed
NCT03967158 — Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice · active not recruiting
NCT03871127 — Ten-Year Outcomes of PRE-COMBAT Trial · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03190057 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seung-Jung Park
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03190057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing